Systematic reviews of (i) comparative studies of depot neuroleptic drugs, and (ii) studies of oral vs depot neuroleptic agents for patients with schizophrenia: clinical, social and economic outcomes- systematic review

David AS, Adams C
Record ID 32001000745
Authors' objectives:

Meta-review of depot antipsychotics
To present a synthesis of the findings on the effectiveness of depot neuroleptic medications in the form of a meta-analysis, and to enablemevidence-based conclusions to be drawn on the comparative efficacy of depots versus placebo, oral drugs, as well as comparative studies of one depot versus another.
Review of attitudes to depot medication
To review the published literature and explore patient and nurse satisfaction with, and attitudes towards depot antipsychotic medication. Specifically, patient satisfaction with depot antipsychotic medication; the patient-preferred setting for its administration; patient preference for depot or oral antipsychotic medication; nurse (and general practitioner) satisfaction with depot antipsychotic medication.
To summarise evidence pertaining to the cost effectiveness and other economic aspects of depot medication.

Authors' recomendations: Meta-review of depot antipsychoticsBy combining the results from individual systematic reviews, it has been possible to summarise a great deal of clinical data on the use of depot neuroleptics. Given the number of potential comparisons and outcomes, there are very few significant results, with the exception of placebo comparisons, which demonstrate the superiority of neuroleptic treatment for schizophrenia in preventing relapse. Those significant findings that emerge from the depot versus oral comparisons suggest a marginal benefit of depots over oral drugs but on only one global outcome measure. Side-effects were in general no worse in the depot group. Relapse rates were very similar and this finding was made with good statistical power. The different depots seem to perform very similarly, with zuclopenthixol showing a slight superiority on one outcome. These conclusions must be tempered by concerns that those patients in whom an advantage from depots may be anticipated, namely those in whom adherence to medication is suboptimal, especially where non-compliance is covert, may not have been represented by the participants in these studies. Furthermore, showing clinically meaningful effects, such as a reduction in relapse rates in community dwelling people with schizophrenia over the long term, can rarely be gleaned from the published literature as it stands. Review of attitudes to depot medicationThere are few data examining patient satisfaction or attitudes regarding depot antipsychotics and even less investigating the attitudes of nurses towards their role in the administration of depots. Higher quality studies are needed. What data there are show a positive attitude to depots from patients, but a broader range of patients needs to be surveyed.
Project Status: Completed
URL for project:
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antipsychotic Agents
  • Costs and Cost Analysis
  • Schizophrenia
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.